• Development of immunotherapies for autoimmune diseases and cancer

KLRG1 – A Compelling Clinical Target in Immune Modulation

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of effector cytotoxic T and NK cells. These cells can be specifically targeted as they express the receptor KLRG1 (killer cell lectin-like receptor G1).

In certain autoimmune diseases, KLRG1-expressing T cells are a major source of chronic tissue damage. In oncology, tumor cells that express E- or N- cadherin inhibit anti-tumor activity of T and NK cells because E- and N-cadherin bind to KLRG1 and KLRG1 functions as an immune checkpoint inhibitory receptor.

KLRG1 was identified as a compelling clinical therapeutic target through Abcuro’s bioinformatic analyses of clinical databases, as well as patient tissue and pathological immune cell transcriptome analyses.

KLRG1: One target, two mechanisms, multiple indications

KLRG1 is a transmembrane receptor. Its ligands are E- and N-cadherin, markers of epithelial and mesenchymal cells, respectively.

Unlike other targets for T cell depletion, KLRG1 expression is restricted to pathogenic, late-differentiated T and NK cells. These KLRG1+ cells are cytotoxic in both autoimmune diseases and in a broad range of cancers.

For patients with inclusion body myositis (IBM), muscle tissue is damaged by KLRG1+ cytotoxic T cells. In the tumor microenvironment, KLRG1 acts as an inhibitory immune checkpoint receptor, interacting with E- and N-cadherin to inhibit the anti-tumor activity of cytotoxic T and NK cells.

LATEST NEWS

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis  Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle … Read More

Featured Post

Abcuro Appoints Niti Goel, M.D., as Chief Medical Officer

Clinical leader brings deep expertise in clinical development, medical and regulatory affairs Newton, MA, June 2, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells today … Read More

Featured Post